Xceleron offers a combination of technology and experimental design you won’t find anywhere else. Throughout the development continuum, Xceleron provides analytical solutions to help you answer questions before they become issues and invaluable foresight to navigate the road ahead.
Xceleron’s use of Accelerator Mass Spectrometry (AMS) technology delivers solutions and insight for a range of pharmaceutical and biobased challenges.
When you’re ready to commit to your most promising compounds, Xceleron will help you leverage and enhance your existing Phase I investigations to assess Phase II-readiness. If you encounter unforeseen problems at any time, we’ll help you solve them with fit-for-purpose solutions.
Xceleron is ISO 17025 accredited and certified to ASTM D6866 for testing biobased products.
AMS is a unique analytical platform because it is exquisitely sensitive, does not suffer from matrix effects, and can be applied across a broad range of compound types, including small molecule and biologics. Xceleron has developed proprietary approaches to analytical method validation and can apply AMS in a clinical setting that is fit for purpose and enabling.
Our clinical research services have supported over 100 pharmaceutical and biotechnology companies from Phase 0 to Phase III and our cutting edge, ultra-sensitive AMS technology has enabled clinical research teams worldwide to drastically reduce their development costs and timelines compared to traditional methods.